Ophthotech Corp President Samir Chandrakant Patel Unloads 18,986 Shares (OPHT)
Ophthotech Corp (NASDAQ:OPHT) President Samir Chandrakant Patel sold 18,986 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $41.08, for a total value of $779,944.88. Following the transaction, the president now directly owns 57,613 shares in the company, valued at approximately $2,366,742. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Ophthotech Corp (NASDAQ:OPHT) traded down 0.26% on Thursday, hitting $40.925. The stock had a trading volume of 55,108 shares. Ophthotech Corp has a 1-year low of $22.61 and a 1-year high of $47.99. The stock’s 50-day moving average is $40.72 and its 200-day moving average is $35.06. The company’s market cap is $1.364 billion.
Ophthotech Corp (NASDAQ:OPHT) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.03. Analysts expect that Ophthotech Corp will post $-2.11 EPS for the current fiscal year.
A number of analysts have recently weighed in on OPHT shares. Analysts at Morgan Stanley raised their price target on shares of Ophthotech Corp from $79.00 to $99.00 in a research note on Tuesday, May 20th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Ophthotech Corp from $40.00 to $51.00 in a research note on Tuesday, May 20th. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Ophthotech Corp from $55.00 to $58.00 in a research note on Tuesday, May 20th. They now have a “buy” rating on the stock.
Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.